**INTRODUCTION**

Melanocytic schwannomas (MSs) are a rare variant of benign Schwann cell neoplasms typically arising in the early middle age with a predilection for extracranial regions.\[5\] Although MS accounts for <1% of all neurolemmomas, the malignant potential of these tumors cannot be undermined.\[1\]

**CASE DESCRIPTION**

A 25-year-old right-handed lady presented to our neurosurgery clinic with progressively worsening complaints of gait disturbance, left ear tinnitus, headaches, and drowsiness for the past 6 months. On neurological examination, she exhibited hyperreflexia in both arms and left lower leg and was unable to walk in a straight line.

Preoperative MRI scans showed a solid-cum-cystic lesion with enhancement along the midline in the posterior fossa extending distally into the cervical spinal cord reaching to the level of upper
endplate of the D1 vertebral body, measuring approximately 13.3 × 4.6 × 3.4 cm [Figure 1]. T1-weighted images showed hypointensity centrally and hyperintensity in the peripheral region, with contrary findings on T2-weighted images. The lesion was causing effacement of the 4th ventricle resulting in hydrocephalus.

We performed a suboccipital craniotomy for resection of the lesion. For improved exposure, part of the C1 ring was removed and cisterna magna opened. A hyper-pigmented and black colored tumor with no clear margins was visualized [Figure 2]. The lesion was soft and fibrous in consistency with moderate vascularization. It was infiltrative and adhesive to the surrounding cranial structures including the brain stem. Therefore, it was decided to debulk as much of the tumor as safely possible without attempting the resection of lesion involving the cord distally. Intraoperative frozen section was inconclusive due to heavy pigmentation. On further analysis, histopathology confirmed a malignant neoplasm of melanocytic origin. Psammoma calcifications with a low Ki-67 index and equivocal HMB45 and Melan-A stains were seen. This made melanocytic schwannoma a more likely possibility than melanoma.

Postoperatively, the patient had an uneventful hospital course and discharged home on the 3rd day after surgery. On the most recent follow-up, her drowsiness and headaches had improved, with some difficulty in walking requiring support. She was referred to medical and radiation oncology services for further management.

**DISCUSSION**

MS may present in the craniovertebral junction (CVJ) with no pathognomonic signs as 29% of cases present asymptptomatically.[2] Correlating clinical findings with radiology are also crucial to delineate MS from melanocytoma and melanoma; MS more likely involves spinal nerves or dorsal root ganglia.[4] While sporadic MS may show variable contrast enhancement, psammomatous MS shows calcific hyperdensities on CT.[7] However, MR imaging is the established gold standard through which the extent of melanization determines clinical suspicion. Sparsely melanotic MS can be mistaken for benign schwannomas, that is, hypointense on T1 and hyperintense on T2.

Spinal instability and progressive neuropathy are strong indications for operative intervention in craniocervical MS.[3] An optimal surgical approach should enable convenient tumor resection and reconstruction without collateral neurological damage. The posterolateral approach is considered the workhorse for craniocervical MS through laminectomy or laminoplasty.[6] Ultimately, the goals of surgery should be
to achieve local tumor control, symptomatic relief, accurate histological diagnosis, and prolong survival time for such patients. Nonsurgical management such as radio-, chemo-, or targeted therapy is recommended for asymptomatic lesions with minimal growth or when complete tumor resection is not possible secondary to local infiltration.

Recent literature advocates for MS to be considered a malignant entity with incompletely excised tumors involving the neurovasculature having the worst prognosis. In the largest series, Torres-Mora et al. found rates of 42% distant metastases, 35% local recurrence, and 27% disease-specific mortality. While metastasis can occur hematogenously or through CSF seeding, the recurrence-free period generally varies from 3 to 20 months for intracranial and intramedullary lesions.

**CONCLUSION**

Posterior fossa MS involving CVJ and spinal cord distally poses a significant neurosurgical challenge in terms of diagnosis and successful intervention. Careful preoperative evaluation and intraoperative prudence are crucial for optimal management.

**Declaration of patient consent**

Patient’s consent not required as patient’s identity is not disclosed or compromised.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Alexiev BA, Chou PM, Jennings LJ. Pathology of melanotic schwannoma. Arch Pathol Lab Med 2018;142:1517-23.
2. Carney JA. Psammomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome. Am J Surg Pathol 1990;14:206-22.
3. Ecker RD, Endo T, Wetjen NM, Krauss WE. Diagnosis and treatment of vertebral column metastases. Mayo Clin Proc 2005;80:1177-86.
4. Hoover JM, Bledsoe JM, Giannini C, Krauss WE. Intramedullary melanotic schwannoma. Rare Tumors 2012;4:e3.
5. Keskin E, Ekmekci S, Oztekin O, Diniz G. Melanotic schwannomas are rarely seen pigmented tumors with unpredictable prognosis and challenging diagnosis. Case Rep Pathol 2017;2017:1807879.
6. Krishnan P, Behari S, Banerji D, Mehrotra N, Chhabra DK, Jain VK. Surgical approach to C1-C2 nerve sheath tumors. Neurol India 2004;52:319-24.
7. Primary Intraosseous Psammomatous Melanotic Schwannoma of the Sacrum Eurorad Eurorad; 2018. Available from: https://www.eurorad.org/case/15643 [Last accessed on 2022 Feb 17].
8. Torres-Mora J, Dry S, Li X, Binder S, Amin M, Folpe AL. Malignant melanotic schwannian tumor: A clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma". Am J Surg Pathol 2014;38:94-105.